After decades of slow progress, the last years have seen a rapid acceleration of the
development of adjuvanted vaccines which have lately been approved for human use …

Seasonal influenza vaccines lack efficacy against drifted or pandemic influenza strains.
Developing improved vaccines that elicit broader immunity remains a public health priority …

The unprecedented increase of life expectancy challenges society to protect the elderly from
morbidity and mortality making vaccination a crucial mean to safeguard this population …

Influenza virus infections are a major public health concern and cause significant morbidity
and mortality worldwide. Current influenza virus vaccines are an effective countermeasure …

Influenza viruses cause annual seasonal epidemics and occasional pandemics of human
respiratory disease. Influenza virus infections represent a serious public health and …

Highlights•New adjuvants are typically a combination of delivery system and an immune
potentiator.•A deeper understanding of innate immunity has helped the discovery of new …

The proportion of the global population aged 65 and older is rapidly increasing. Infections in
this age group, most recently with SARS-CoV-2, cause substantial morbidity and mortality …

There is a need for improved influenza vaccines. In this study we compared the antibody
responses in humans after vaccination with an AS03-adjuvanted versus nonadjuvanted …

The progressive increase of the aged population worldwide mandates new strategies to
ensure sustained health and well-being with age. The development of better and/or new …

In modern vaccines, adjuvants can be sophisticated immunological tools to promote robust
and long-lasting protection against prevalent diseases. However, there is an urgent need to …